<DOC>
	<DOCNO>NCT00485966</DOCNO>
	<brief_summary>This Phase 2 , open-label , multicenter , efficacy , safety , pharmacodynamic study CX-3543 patient relapse refractory B-cell chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Study Evaluating Effects CX-3543 Patients With Relapsed Refractory B-Cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>The purpose trial evaluate response rate , safety , pharmacodynamic effect , duration response CX-3543 patient relapse refractory B-cell CLL .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Patients Bcell CLL indication treatment National Cancer Institute ( NCI ) Working Group criterion . Measurable disease ( lymphocytes ≥ 5,000/microliter , palpable lymphadenopathy bone marrow involvement &gt; 30 % ) . Males females 18 year age older . Received minimum one prior purine analogbased chemotherapy regimen ( e.g. , fludarabine , cladribine , pentostatin ) one monoclonal antibody therapy ( e.g. , Campath Rituxan ) ≤ 4 chemotherapy regimen . Patients must central intravenous ( IV ) access , agree insertion central line . All previous cancer therapy , radiation , hormonal therapy surgery , must discontinue least 28 day prior start treatment . Any cytotoxic chemotherapy must discontinue 28 day prior start treatment . Acute toxicities prior therapy must resolve Grade ≤ 1 baseline . Normal oxygen saturation pulse oximetry room air . Hemoglobin ≥ 9 gm/dL ( may posttransfusion ) . Platelet count ≥ 25,000/microliter . Total bilirubin &lt; 2 X upper limit normal ( ULN ) , ALT AST &lt; 2 x ULN . Serum creatinine within normal limit OR calculate creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level upper normal limit institution ECOG Performance Status ≤ 1 . Anticipated survival least 3 month . For men woman childproducing potential , use effective contraceptive method study one month discontinuation treatment . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return clinic require assessment . Pregnant nursing woman . Severe chronic obstructive pulmonary disease hypoxemia uncorrectable pulmonary compromise . Seizures control anticonvulsant therapy . Participation investigational drug study within 28 day quarfloxacin administration . Patients second malignancy require active treatment . Active symptomatic bacterial , fungal , viral infection include active HIV viral ( A , B , C ) hepatitis . Clinically significant bleeding event within last 3 month , unrelated trauma , underlying condition would expect result bleed diathesis . Patients exhibit allergic reaction similar structural compound ( e.g. , fluoroquinolones ) formulation ( contain buffer and/or polyethylene glycol ) . Patients life functionthreatening CLL complication ( e.g. , cord compression , hemolytic crisis , urinary tract obstruction ) . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Adult Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>B-CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>B-cell CLL</keyword>
</DOC>